Cerebra Integr. (CEREBRAINT)
Asset PlayScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹2.57 |
| Market Cap | ₹31.14 Cr |
| P/E Ratio | 0 |
| ROCE | -15.41% |
| ROE | -56.47% |
| Dividend Yield | 0% |
| Profit Growth | 54.22% |
| Debt/Equity | 0.48 |
| Sales Growth | -81.87% |
| Promoter Holding | 0.84% |
| 52-Week Range | ₹2.38 — ₹10.08 |
| Sector | IT - Hardware |
| Book Value | ₹8.31 |
Strengths
- Apparent asset cushion: price ₹4.94 vs book value ₹14.84, P/B 0.33.
- Low leverage: debt/equity at 0.30, so no immediate debt overhang.
- Small ₹57 Cr market cap gives optionality if any restructuring or revival happens.
Concerns
- Promoter holding is just 0.84%, indicating almost no skin in the game.
- Sales collapsed by 92.36%, and latest quarterly revenue is only ₹1 Cr.
- Latest quarter net loss of ₹17 Cr is roughly 30% of the entire market cap; ROE -25.98% and ROCE -15.41% show severe value erosion.
- Piotroski F-Score of 2/9 points to very weak financial health.
AI Analysis
From a Graham-Buffett lens, Cerebra Integr. fails the first test: does the business have earning power? A P/E of 0.00 is not a sign of cheapness—it means there are no earnings. Sales are down 92.36%, and the latest quarter recorded just ₹1 Cr of revenue with a ₹17 Cr net loss. That quarterly loss is roughly 30% of the entire market cap of ₹57 Cr. The machine is destroying value faster than the market is giving it credit. The only lure is the balance sheet. Book value is ₹14.84 against a share price of ₹4.94, so the stock trades at 0.33 times book. But Graham would demand that I understand whether that book value is real and protected. ROE is -25.98%, ROCE is -15.41%, so the company is bleeding equity every quarter. With a debt/equity of 0.30, leverage is not the immediate problem; erosion is. Given a Piotroski score of 2/9, the financial health is weak. Worst of all, promoter holding is just 0.84%. In a small, distressed company, I want owners with substantial skin in the game. A 0.84% promoter stake gives me little confidence that management’s interests are aligned with minority shareholders. There is no dividend, no profitability, and no visible growth. This is not a durable compounding machine. It might look like an asset play because of the discount to book value, but without evidence that the assets can be realized or the losses halted, the discount may be a trap. I would wait for stable revenue, credible management action, and proof that book value is not shrinking.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer